Skip to content

Effectiveness and cost effectiveness of Problem Management Plus (PM+) plus treatment as usual (TAU) vs. treatment as usual (TAU) in the management of common mental disorders in a tertiary mental health care facility in Pakistan: a single blind randomised controlled trial (RCT)

Effectiveness and cost effectiveness of Problem Management Plus (PM+) plus treatment as usual (TAU) vs. treatment as usual (TAU) in the management of common mental disorders in a tertiary mental health care facility in Pakistan: a single blind randomised controlled trial (RCT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000381482
Enrollment
192
Registered
2016-03-23
Start date
2015-07-23
Completion date
2016-08-20
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

WHO and The University of New South Wales have developed Problem Management Plus (PM+), a low-intensity psychological intervention to help people with emotional and practical problems. The objective of the study is to evaluate the feasibility, efficacy and cost-effectiveness of PM+ strategy as a psychological intervention for clients with common mental disorders vs. treatment as usual (TAU).

Interventions

The name of the intervention is Problem Mangement Plus (PM+). It is a Cognitive Behaviour Therapy (CBT) based intervention for clients experiencing symptoms of depression and anxiety or any other stress related condition. PM+ is a trans-diagnositic, evidence-based intervention consisting of 5 weekly, individual face-to-face sessions and each session is for approximately 90 minutes. A designated psychologist trained in PM+ by the master trainer will deliver the 5 individual sessions to their desi

The name of the intervention is Problem Mangement Plus (PM+). It is a Cognitive Behaviour Therapy (CBT) based intervention for clients experiencing symptoms of depression and anxiety or any other stress related condition. PM+ is a trans-diagnositic, evidence-based intervention consisting of 5 weekly, individual face-to-face sessions and each session is for approximately 90 minutes. A designated psychologist trained in PM+ by the master trainer will deliver the 5 individual sessions to their designated client. These sessions will be based on discussion focusing on 4 strategies; managing stress, managing problems, get going keep doing, strengthening social support. The intervention group receives PM+ in addition to Treatment as usual (TAU). TAU consists of non-specific supportive counselling sessions and pharmacotherapy (antidepressants, anxiolytics, sedative and hypnotics etc) that clients receive at the tertiary mental healthcare facility. A register of attendance of the clients for their five PM+ sessions is being maintained.

Sponsors

Human Development Research Foundation
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Clients of either gender will be included in the study, the age of participants from 18 to 60 years, GHQ score >2, and WHO DAS score > 16. GHQ-12 is the most extensively used screening instrument for common mental disorders, in addition to being a more general measure of psychiatric well-being, whereas, WHO DAS is a generic assessment instrument assessing health and disability.

Exclusion criteria

clients with severe mental disorder (for example, mania, seizures, psychosis, alcohol or drug-use dependence) and imminent suicide risk (Assessed using formal suicide risk assessment based on a WHO measure). reports of acute distress in the past month and clients that are residing outside of the study area and unable to attend for regular weekly PM+ sessions.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 26, 2026